Cyclic Peptides with RNase A Inhibitor Activity Based on Amino Acid Sequences Screened from the Fv-Antibody Library
ACS Biomaterials Science & Engineering · 2026
DOI: 10.1021/acsbiomaterials.6c00910 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2026. Verfasst von Jeong Soo Sung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Materials Science and Engineering, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul 03722, South Korea. Hauptthemen laut MEDLINE: Peptides, Cyclic, Ribonuclease, Pancreatic, Enzyme Inhibitors. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (Originalsprache)
Ribonuclease A (RNase A) is a pancreatic enzyme that rapidly degrades single-stranded RNA and is widely used as a representative enzyme in studies of RNase-mediated RNA degradation. Therefore, effective RNase A inhibitors are needed to regulate RNase activity and protect RNA from enzymatic degradation. Fv-antibodies represent the antigen-binding region of immunoglobulin G (IgG) and are composed of complementarity-determining regions (CDRs) and framework regions (FRs). Previously, CDR3 sequences with RNase A inhibitory activity were screened using RNase A as a probe from an autodisplayed Fv-antibody library constructed by site-directed mutagenesis of the 11-residue CDR3 region and expressed on the outer membrane of Escherichia coli. In this study, these screened CDR3 sequences were synthesized as cyclic peptides by introducing cysteine residues at both the N- and C-termini, enabling intramolecular disulfide bond formation. The metabolic stability of the peptides was enhanced through cyclization, as demonstrated by a significant increase in half-life (t1/2) during liver microsome assays. The RNase A inhibitory activities of Fv-antibodies, linear peptides, and cyclic peptides were analyzed using cyclic cytidine monophosphate (cCMP) hydrolysis, fluorogenic RNA probe-based fluorescence, and RNA cleavage assays. Among these formats, cyclic peptides exhibited enhanced RNase A inhibitory activity compared with both Fv-antibodies and linear peptides. The influence of peptide conformation on RNase inhibitory activity was further analyzed using docking simulation. These results demonstrated that cyclization of RNase A-inhibitory CDR3 sequences improved inhibitory activity and supported the development of cyclic peptide-based RNase A inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Materials Science and Engineering, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul 03722, South Korea.
- Korea Institute of Science and Technology (KIST), Seoul 02792, South Korea.
- Institute of Pharmaceutical and Medical Chemistry, Westfälischen Wilhelms-Universität Münster, Muenster 48149, Germany.
ORCID-Profile: Hyung Eun Bae, Min-Jung Kang, Joachim Jose, Jae-Chul Pyun
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
Zitieren
APA
Sung, J. S., Kim, H. I., Song, H. W., Park, W. W., Bae, H. E., Kang, M. J., Jose, J., & Pyun, J. C. (2026). Cyclic Peptides with RNase A Inhibitor Activity Based on Amino Acid Sequences Screened from the Fv-Antibody Library. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.6c00910
Vancouver
Sung JS, Kim HI, Song HW, Park WW, Bae HE, Kang MJ, et al. Cyclic Peptides with RNase A Inhibitor Activity Based on Amino Acid Sequences Screened from the Fv-Antibody Library. ACS Biomaterials Science & Engineering. 2026. doi:10.1021/acsbiomaterials.6c00910
BibTeX
@article{Sung2026,
author = {Sung, Jeong Soo and Kim, Hye-In and Song, Hyun-Woo and Park, Won-Woo and Bae, Hyung Eun and Kang, Min-Jung and Jose, Joachim and Pyun, Jae-Chul},
title = {Cyclic Peptides with RNase A Inhibitor Activity Based on Amino Acid Sequences Screened from the Fv-Antibody Library},
journal = {ACS Biomaterials Science & Engineering},
year = {2026},
doi = {10.1021/acsbiomaterials.6c00910}
}
EUVIMED